Exavir Therapeutics Completes $4M Seed Financing from Key Investors NEW YORK and OMAHA, Neb., May 23, 2022 (GLOBE NEWSWIRE) -- Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that...

Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...

Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...

Antidiabetics Market will surge at 10.6% CAGR from 2018 to 2024: Global Market Insights, Inc. Sellbyville, Delaware, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Global Antidiabetics Market will surpass USD 110 billion by 2024; according to a new research report by Global Market Insights, Inc....

Antidiabetics Market to surpass $110 Billion by 2024: Global Market Insights, Inc. Ocean View, Delaware, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Antidiabetics Market is poised to reach USD 110 billion by 2024; according to a new research report by Global Market Insights, Inc....